2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 900

Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study
Abstract Number: 901

Changes in Quantitative Scleroderma Lung CT Measures in Patients Treated with Cyclophosphamide or Transplantation
Abstract Number: 902

Longitudinal Trends in Clinical Disease Features after Myeloablative Autologous Stem-Cell Transplantation or Cyclophosphamide in Severe Scleroderma
Abstract Number: 903

Riociguat in Patients with Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Phase IIb Study (RISE-SSc)
Abstract Number: 904

Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Results of the Four-Year Study of Rituximab in ANCA-Associated Vasculitis Registry
Abstract Number: 905

Serum Interleukin-6 Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Abstract Number: 906

Defining the Gut Microbiome in Patients with ANCA-Associated Vasculitis
Abstract Number: 907

Characterization of Preferential Recognition of a Chimeric Recombinant Proteinase 3 Variant By Anti-Neutrophil Cytoplasmic Antibodies
Abstract Number: 908

Early Prediction of Long-Term Evolutionary Profiles of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Based on Baseline and Follow-up Characteristics
Abstract Number: 909

Temporal Trends of ANCA-Associated Vasculitis Comorbidities: Results from a National, Longitudinal, Matched-Cohort Study
Abstract Number: 910

In Diagnostic Prevalence and Treatment Patterns of Male and Female Ankylosing Spondylitis Patients in the United States, 2006-2016
Abstract Number: 911

Demographic and Clinical Characteristics Reflect Differences in Osteoarthritis Phenotypes of the Lumbar Spine: The Johnston County Osteoarthritis Project
Abstract Number: 912

Association of Adiposity Measures in Childhood and Adulthood with Knee Cartilage Thickness, Volume and Bone Area in Young Adults
Abstract Number: 913

Risk Factors for Knee Pain Exacerbation on Walking: A within-Person Knee-Matched Study
Abstract Number: 914

Increased Adverse Childhood Experiences in Children with Arthritis: An Analysis of the National Survey of Children’s Health

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].